Project Grant R21AI189861
Award Date
7/10/25
Completion Date
6/30/27
Dollars Obligated
$411K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $188,544 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant will fund research to better understand the molecular mechanisms underlying SARS-CoV-2 infection and innate immune regulation. Specifically, the project aims to examine the role of the protein SAMHD1 in regulating SARS-CoV-2-induced inflammation in primary human airway epithelial cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $437,895 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Research Foundation For The State University Of New York (RF SUNY) to investigate the role of the 90K protein in SARS-CoV-2 infection. The key objectives are to provide mechanistic evidence on the effect of 90K during SARS-CoV-2 infection and to identify how SARS-CoV-2 accessory proteins may counteract 90K's antiviral activity. This...
This Project Grant award of $582,618.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant supports research to determine the mechanisms by which RNA N6-methyladenosine (m6A) and pseudouridine (Ψ) modifications modulate SARS-CoV-2 replication, gene expression, immunity, and pathogenesis. Key activities include using CRISPR-Cas9 to knock out host RNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $867,563 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rockefeller University. The grant supports the development of a pioneering class of nanobodies engineered from llama immune systems to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. Key goals include strategically expanding nanobody repertoires, identifying...
This federal Project Grant award of $448,688.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research conducted by the Oklahoma Medical Research Foundation (OMRF) to investigate the mechanisms by which Notch signaling regulates interactions between airway epithelial cells and myeloid immune cells during SARS-CoV-2 infection. The goal is to advance understanding of how...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Vermont & State Agricultural College (UVM) in the amount of $438,983. The award, which runs from July 8, 2025 to June 30, 2027, will fund research to study the biological impact of a stable nucleocapsid (N) protein dimer formation in SARS-CoV-2. Specifically, the research aims to characterize viral growth...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $116,022 Project Grant under CFDA 93.855 - Allergy and Infectious Diseases Research to The University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct studies on the SARS-CoV-2 main protease (Mpro) dimerization mechanism. The key objectives of this grant are to: Use quantitative luciferase-based reporter assays developed by the researchers to study the Mpro dimerization mechanism and identify...
This federal Project Grant award of $705,557 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to better understand the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The primary objectives are to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, and to define the effector mechanisms of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $899,935 to the Scripps Research Institute to identify novel B cell epitopes on the SARS-CoV-2 spike protein and other human coronaviruses. The goal is to uncover broadly neutralizing antibody epitopes that can inform the design of next-generation COVID-19 vaccines and therapeutics, enhancing pandemic preparedness. The...